May 25, 2018
A recent Federal Circuit decision applying the rarely-invoked printed matter doctrine to invalidate a respiratory drug patent could give litigants another way to challenge patents and get in patent-eligibility arguments that otherwise can't be made in inter partes reviews, attorneys say.
May 16, 2018
The Federal Circuit on Wednesday upheld the Patent Trial and Appeal Board's decision to invalidate the bulk of a Mallinckrodt patent on respiratory drug Inomax, then canceled an additional claim that judges said the board wrongly interpreted.